Douglas Van Oort
Executive Chairman &  Chief Executive Officer

Mr. VanOort has held executive leadership positions with several world-class Fortune 500 firms and rapidly-growing ventures during his 30-year career. He spent over 10 years in health-care services, first as Executive Vice President and Chief Financial Officer of Corning Life Sciences, Inc. and then as Senior Vice President, Operations at Quest Diagnostics, Inc.
At Corning Life Sciences, he helped build and engineer the spinoff of two leading publically-traded NYSE life-science companies, Quest Diagnostics, Inc. and Covance, Inc, ultimately joining Quest at the time of the spin-off. During his tenure with Corning Life Sciences and then Quest, he was part of the team that successfully transformed the company into the largest independent clinical laboratory testing company in the United States, growing it from approximately $500 million in revenue in 1989 to approximately $1.5 billion in revenue in 1998.

During the past 10 years, Mr. VanOort founded, invested in, and built businesses in a variety of industries. He currently serves as Operating Partner at Summer Street Capital Partners, Managing Director of Conundrum Capital Partners, and as a member of the Board of several private-equity held companies.

Robert P. Gasparini, M.S., CLSp(CG), CLDir
President & Chief Scientific Officer

Bob Gasparini is President & Chief Scientific Officer for NeoGenomics Laboratories. Prior to assuming a key leadership role at NeoGenomics, Mr. Gasparini successfully held the Director position of the Genetics Division for US Pathology Labs, Inc. Prior to US Labs, Mr. Gasparini was the Molecular Marketing Manager for Ventana Medical Systems.
Prior to Ventana, Mr. Gasparini was the Assistant Director of the Cytogenetics Laboratory for the Prenatal Diagnostic Center an affiliate of Mass General Hospital and part of Harvard University. While at the Prenatal Diagnostic Center, Mr. Gasparini was also an Adjunct Professor at Harvard University.

Mr. Gasparini is a licensed Clinical Laboratory Director and an accomplished author in the field of Cytogenetics and FISH. He received his BS degree from University of Connecticut in Biological Sciences and his Master of Health Science degree from Quinnipiac University in Laboratory Administration.

Michael T. Dent, M.D.
Director

Dr. Dent is our founder and Chairman of the Board. Dr. Dent was our President and Chief Executive Officer from June 2001, when he founded NeoGenomics, to April 2003. From April 2003 until April 2004, Dr. Dent served as our President and Chief Medical Officer.
Dr. Dent founded the Naples Women's Center in 1996 and continues his practice to this day. He received his training in Obstetrics and Gynecology at the University of Texas in Galveston.

He received his M.D. degree from the University of South Carolina in Charleston, S.C. in 1992 and a B.S. degree from Davidson College in Davidson, N.C. in 1986.

He is a member of the American Association of Cancer Researchers and a Diplomat and fellow of the American College of Obstetricians and Gynecologists.

He sits on the Board of the Florida Life science Biotech Initiative.

Steven C. Jones
Executive Vice President, Finance

Mr. Jones has served as a director and Chief Financial Officer since October 2003. He is Chairman of the Board of Aspen Capital Group, a diversified financial services firm. He also serves as managing member of the general partner of Aspen Select Healthcare, LP, a private equity fund established to make investments in the healthcare industry.
Prior to that, Mr. Jones was a chief financial officer at various public and private companies and was a Vice President in the Investment Banking Group at Merrill Lynch & Co. Mr. Jones received his B.S. degree in Computer Engineering from the University of Michigan in 1985 and his MBA from the Wharton School of the University of Pennsylvania in 1991.

George G. O'Leary
Director

Mr. O’Leary is currently the Chairman and acting Chief Executive Officer of Futuremedia PLC. Mr. O’Leary is also President of SKS Consulting of South Florida Corp. which he started in 2000 and is currently on the Board of Directors of NeoGenomics, NeoMedia, Smartire, Isonics and Falcon Industries. Mr. O’Leary is still a consultant to NeoGenomics and was acting Chief Operating Officer from October 2004 to March 2006.
Mr. O’Leary was CEO and President of Communication Resources Incorporated (CRI) from 1996 to 2000. During that time, he grew annual revenues from $5 million to $40 million.

Prior to CRI, Mr. O’Leary held various positions including VP of Operations for Cablevision Industries from 1987 to 1996.

Mr. O’Leary was a CPA with Peat Marwick Mitchell from 1984 to 1987. He received his BBA degree in Accounting from Siena College in Albany, New York.

Peter M. Peterson
Director

Mr. Peterson is the founder of Aspen Capital Partners, LLC which specializes in capital formation, mergers and acquisitions, divestitures, and new business start-ups. Mr. Peterson is also the Chairman and founder of CleanFuel USA.
Prior to forming Aspen Capital Partners, Mr. Peterson was Managing Director of Investment Banking with H. C. Wainwright & Co. Prior to joining Wainwright, Mr. Peterson was President of First American Holdings and Managing Director of Investment Banking.

Prior to First American, he served in various investment banking roles and was the co-founder of ARM Financial Corporation. Mr. Peterson was one of the key individuals responsible for taking ARM Financial public on the OTC market and the American Stock Exchange.

Under Mr. Peterson’s financial leadership, ARM Financial Corporation was transformed from a diversified holding company into a national clinical laboratory company with more than 14 clinical laboratories and ancillary services with over $100 million in assets.

Mr. Peterson also served as President and founder of the Paramount Group, Inc., a privately held real estate company specializing in financing and project consulting.

He has also served as an officer or director for a variety of other companies, both public and private. Mr. Peterson earned a Bachelor of Science degree in Business Administration from the University of Florida.

William J. Robison
Director

William J. Robison spent his entire working career with Pfizer Inc, which began as a sales representative in Pharmaceuticals and he retired after almost 40 years in charge of Worldwide HR and as Executive Vice President of the Company.
He is a graduate of Univ. of Louisiana-Monroe with a BS in Mathematics. Upon graduation, he was commissioned as a Second Lieutenant in the United States Marine Corps and subsequently attained the rank of Captain. He served in the Far East.

He serves on the Board of Trustees for the Univ. of Louisiana-Monroe, is a Founding Member of the Marine Corps Museum, and serves as a member of the Board of Directors for Peri-Cor Therapeutics, Inc., MWI Veterinary Supply Co. Inc., and NeoGenomics.

Marvin E. Jaffe, M.D.
Director

Dr. Jaffe, who is retired, spent his entire working career in the pharmaceutical industry and has been responsible for the pre-clinical and clinical development of new drugs and biologics in nearly every therapeutic area. He began his career at Merck & Co and spent 18 years with Merck, rising to the position of Senior Vice-President of Medical Affairs.
After leaving Merck, Dr. Jaffe became the founding President of the R.W. Johnson Pharmaceutical Research Institute (PRI), a Johnson & Johnson Company. PRI was established for the purpose of providing globally integrated research and development support to several companies within the J & J pharmaceutical sector, including Ortho Pharmaceutical, McNeil Pharmaceutical, Ortho Biotech and Cilag.

Dr. Jaffe retired from Johnson & Johnson in 1994 and currently serves as a consultant and board member to various companies in the biopharmaceutical and biotechnology industries. He is currently a Director of Immunomedics, Inc. He was also on the Boards of Genetic Therapy, Inc., Vernalis Group, plc., Celltech Group, plc. and Matrix Pharmaceuticals which were acquired by other companies. He is on the Scientific Advisory Boards of Health Care Ventures, Endpoint Merchant Group, Newron Pharmaceuticals and PenWest Pharmaceuticals.

APVX Login

Our clients can manage their case load efficiently with our APVX Reporting System.

Client Login Sign In

Latest Press Releases


ALL Press Releases